echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In order to expand the pipeline, a large number of pharmaceutical companies are spending huge sums of money to initiate acquisitions

    In order to expand the pipeline, a large number of pharmaceutical companies are spending huge sums of money to initiate acquisitions

    • Last Update: 2022-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Industry News] Recently, Warby Medical announced that it has completed the acquisition of phenox, a global neurointerventional company located in Germany, and its subsidiary femtos
    .

    The acquisition, with a total value of approximately EUR 500 million (including milestone payments), will create significant synergies in terms of product portfolio and market coverage, providing multi-faceted neurointerventions for patients in key markets such as China, the United States, Europe and Japan Technologies and Solutions
    .

    According to the data, Warby Medical Holdings Limited ("Woby Medical" or the "Company") is a global innovative medical technology company focused on the development and commercialization of neurointerventional medical device products for the treatment of stroke
    .

    For this acquisition, the relevant person in charge of Warby Medical said that it is a further extension of the cooperation between the two parties, and it is also a key step for Warby Medical to realize the company's vision
    .

    The combined company will take root in the two key markets of Europe and China, and further expand its presence in the US and Japan
    .

    Benefiting from the highly complementary product lines of the two companies, after the merger, Warby Medical will have a full-category, world-class neurointerventional product portfolio
    .

    With the expansion of product categories, enhancement of R&D capabilities and expansion of market coverage, Wobi Medical will also have a more significant competitive advantage, or become a large-scale enterprise in the field of neurointerventional devices
    .

       In recent years, industrial chain extension or product line expansion through investment and acquisition has become very common in the pharmaceutical field
    .

    It is understood that since the beginning of this year, there have been many local pharmaceutical companies that have expanded their product lines by buying and buying
    .

       For example, on March 9, Proton shares announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire Kaihui Medicine held by Ruizhi Chemical at a price of RMB 266 million in cash.
    100% equity in the industry
    .

    After the completion of this transaction, the company will hold 100% equity of Kaihui Pharmaceutical, and Kaihui Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the scope of the company's consolidated financial statements
    .

       On February 18, Haoyuan Pharmaceutical announced that the company intends to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% of the shares of Yaoyuan Medicine held by them.
    The transaction price is not expected to exceed 420 million yuan
    .

    According to the data, Yaoyuan Pharmaceutical is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations to new drug developers, especially in the field of preparation CMC business
    .

    It is reported that this acquisition is expected to continue to extend the service chain of Haoyuan Pharmaceuticals, make up for shortcomings, and create a CRO/CDMO/CMO industry-wide service platform that integrates "intermediate-API-formulation"
    .

       On February 8, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center
    .

    The main business of Zhuhai Zhifan is to invest in Mingkang Bio, and it holds a registered capital of Mingkang Biology of RMB94,452,900 (of which RMB32,866,500 has not been paid), accounting for approximately 51% of the total registered capital of Mingkang Biology as at the date of this announcement
    .

       Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.